

PRESS RELEASE

PERSONALIZED MEDICINE: PRESENTING “DIANA”, THE DIAGNOSTIC BOOTH THAT SIMPLIFIES CLINICAL EXAMS AND MONITORS THE EFFECTIVENESS OF TREATMENTS

The project stems from the synergy between Antares Vision Group, Isinnova and the National Research Center “Development of gene therapy and drugs with RNA technology”. The first prototype will be ready at the end of June 2025

Travagliato, (Brescia), 17 December 2024 - An innovation that promises to revolutionize medical diagnostics. It's called **DIANA** (*Diagnostica Intelligente per Analisi Non Invasiva Avanzata* - Intelligent diagnostics for advanced non-invasive analyses) and is the result of a partnership between **Antares Vision Group**, Italian multinational, leading provider in Track & Trace systems and quality control, and **Isinnova**, a Brescia-based SME, which enables and makes technological innovation accessible, with the strategic support of the **National Research Center “Development of gene therapy and drugs with RNA technology”** funded by the NRRP.

DIANA is a booth that combines advanced non-invasive technologies, and represents a real step towards **personalized medicine**, seeking to improve the quality of treatments and patients' lives. The objective is to accelerate and simplify diagnoses, monitor **the effectiveness of treatments** in real time, and support the development of bespoke drugs for the patient, offering a diagnostic platform able to perform **over 60 non-invasive exams in just 15 minutes**. The exams, which include tests on electrical-brain activity, cardiac activity, blood composition, body composition, electrical-muscular activity and lung capacity, provide a complete and personalized picture of a patient's health, reducing the time and costs of traditional analyses.

*“To accomplish this project, we used technologies that were already known or were at an experimental stage, and we combined them to create DIANA, thanks to the efforts of our team of experts - **state Cristian Fracassi and Marco Silvestri from ISINNOVA, CEO and head of the Diana project respectively**. The objective of the booth, which we would like to create different versions of, based on the area of application, is not to replace doctors, but to speed up the work of health professionals”.*

*“The potential of DIANA combined with gene therapy protocols can help us to monitor the effectiveness of drugs with RNA technology in real time, which we are developing in our role as National Research Center - **states prof. Rosario Rizzuto, President of the National Research Foundation for the development of gene therapy and drugs with RNA technology**. Supporting a technology like DIANA's means reducing research time, simplifying diagnostic steps, but above all finding increasingly accurate and sustainable treatments”.*

*“DIANA represents a paradigm shift, and paves the way for a faster, more efficient and above all personalized medicine, focused on the patient – **explains Alberto Albertini, Innovation Center Director of Antares Vision Group**. Technology makes it possible to apply scientific research for the benefit of everyone's health. Moreover, the partnership between the three entities involved in the project, demonstrates how synergy between research bodies, companies and universities can be transformed into real solutions for medical and technological progress”.*



PRESS RELEASE

The first prototype of DIANA, called DIANA-ATMP, will be ready mid-2025, and will be used at the National RNA & Genetherapy Center to monitor patients undergoing gene and advanced pharmacological treatments.

DIANA's contribution will be fundamental in the **data collection** stage, as it will speed up the process of **acquiring and integrating** information in a short timeframe, at a high level of quality, also as regards remote healthcare with respect to large medical research centers. The technology will enable different sources to be combined in a single integrated system, simplifying data access and analysis for doctors. This approach, together with the opportunity to personalize treatment plans based on the specific characteristics of each patient, will enable more targeted and effective treatments to be offered, as well as creating a more complete archive to study specific diseases.

Antares Vision Group is working with Isinnova on industrializing innovative solutions, and in 2022, acquired a 15% stake of the Brescia-based SME's share capital. The Italian multinational is also a technological partner of excellence in the research and innovation projects funded by the European Union, and in 2023, signed an agreement with the National Research Center "Development of gene therapy and drugs with RNA technology" as founder, which envisages a commitment to make its solutions available in digital healthcare, smart digital innovation, software platforms, digital twin systems, technologies for traceability and serialization, origin and certification of drugs and products, quality inspections with computer vision, IoT sensors and data analysis, also thanks to Artificial Intelligence.

ANTARES VISION GROUP

Antares Vision Group is an Italian multinational listed since 2021 on the Euronext STAR Milan segment (EXM, AV:IM), which ensures product safety and supply chain transparency through innovative technologies for quality control, traceability, and integrated data management. It operates in the Life Science sectors (Pharmaceuticals, Medical Devices, Hospitals), Cosmetics, and FMCG (Fast-Moving Consumer Goods), supporting companies in digitalizing processes to improve efficiency, productivity, and visibility. Antares Vision Group is a global leader in pharmaceutical traceability, supplying the world's top producers (over 50% of the top 20 multinational Companies) and numerous Government authorities. With a presence in over 60 countries, more than 1,200 employees, and a network of around 40 international partners. It achieved revenues of €214 million in 2023, marking a 7% increase compared to 2022. www.antareshvisiongroup.com

ISINNOVA

Founded in 2014, Isinnova seeks to be a research and development center, a provider of innovation services, and defines itself as a "Knowledge-Intensive Business Service". In addition, it acts as an intermediary, to transfer ideas and technologies from a sector that designs them to another that has a technological requirement or a problem to solve. Cristian Fracassi is CEO and founder of Isinnova, a building-architectural engineer, with a doctorate in Materials Engineering and a Master in economics and development of business ideas. Knight of merit of the Italian Republic for the Easy-Covid 19 project, he is the inventor of numerous patents and has strong passion for innovation and the search for tangible solutions. In 2020, he received the "Mother Teresa Memorial Award for Social Justice 2020", considered the Nobel prize for social impact. www.isinnova.it



PRESS RELEASE

NATIONAL RESEARCH CENTER "DEVELOPMENT OF GENE THERAPY AND DRUGS WITH RNA TECHNOLOGY"

The National Research Center "Development of gene therapy and drugs with RNA technology" is one of five centers funded with over Euro 320 million, by the European Union (NRRP Mission 4 - Education and Research) as part of the NextGeneration EU (NGEU), engaged in the development of new gene therapies and the identification of new therapeutic targets to be transformed into innovative pharmacological products based on RNA. Created from a project proposal presented by the University of Padua together with other partners, the Center is today coordinated by a Foundation of the same name, which acts as a HUB, involving 32 universities and research institutes, and 14 private companies, for a total of 1000 scientists already at work at the entities and over 500 researchers and PhD students recruited ad hoc. The research projects are organized into 10 Spokes, 5 of which are vertical dedicated to research, and 5 horizontals, which focus on technological development. <https://www.rna-genetherapy.eu/>

FOR FURTHER INFORMATION

Antares Vision Group

Alessandro Baj Badino – alessandro.bajbadino@antaresvision.com

Raffaella Mora – raffaella.mora@partner.antaresvision.com

Press contacts: Federica Menichino – federica.menichino@axel-comm.it

Isinnova

Marco Silvestri – marco.silvestri@isinnova.it, info@isinnova.it

National Research Center "Development of gene therapy and drugs with RNA technology"

Press contacts

Roberta Stumpo: 3291134706 – roberta.stumpo@adnkronos.com

Stefano Colace: 3472371576 – stefano.colace@adnkronos.com

Andrea Nalon: 3280885794 – andrea.nalon@adnkronos.com